Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.40 |
| ▸ | CES2 | O00748 | 5/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | GAPDH | P04406 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674145 | 0.91 | CES2 (0.44) | CES1CES2TRPA1ALDH1A1TSHR | |
| SCHEMBL20942862 | 0.90 | CES1 (0.43) | CES1CES2TRPA1ALDH1A1TP53 | |
| SCHEMBL3915868 | 0.86 | CES1 (0.40) | CES1CES2TRPA1ALDH1A1TP53 | |
| SCHEMBL3915869 | 0.86 | CES1 (0.40) | CES1CES2TRPA1ALDH1A1TP53 | |
| SCHEMBL20942865 | 0.85 | — | — | |
| SCHEMBL19976119 | 0.85 | — | — | |
| SCHEMBL1701354 | 0.84 | CES2 (0.46) | CES1CES2TRPA1ALDH1A1TSHR | |
| SCHEMBL1701125 | 0.84 | CES2 (0.46) | CES1CES2TRPA1ALDH1A1TSHR | |
| SCHEMBL6627036 | 0.83 | TRPA1 (0.48) | CES1CES2TRPA1ALDH1A1DDAH1 | |
| SCHEMBL16012618 | 0.81 | CES2 (0.48) | CES1CES2TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG A CORPORATION OF SWEDEN (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939198-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939200-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | CES1 1631/4885CES2 3237/4885TRPA1 1123/4885 |
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | CES1 1807/4885CES2 2218/4885TRPA1 1897/4885 |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ADORA1, CXCR6, NR0B1 | CES1 3222/4885CES2 4157/4885TRPA1 2362/4885 |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | CES1 1995/4885CES2 3095/4885TRPA1 2110/4885 |
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | ADORA1, SLC28A1, ADORA2A | CES1 1830/4885CES2 3684/4885TRPA1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.